Recombinant proteins are the novel combination of genes that can be used in the formation of DNA. Recombinant DNA technology helps in the production of wild type and modified human, mammalian proteins in bulk quantities. The proteins are made from cloned DNA sequences that generally encode an enzyme or protein with the known function. They are made through genetic engineering, which is also called gene splicing or recombinant DNA technology. The recombinants can be obtained by putting human, animal, or plant genes into the genetic material of mammalian, bacteria, or yeast cells. These microorganisms can be used as factories or producers to make proteins for medical, academic, and research uses. The recombinant DNA is inserted into expression vectors that contain the promoter, ribosome binding site, and terminator.
COVID-19 scenario analysis:
The foremost part done by the government was to shake hands with the Pharmaceutical and Biotechnology industries in order to combat with the outbreak of the pandemic. The government invested a higher amount on the development of various vaccines which could ultimately help in the managements of the people infected with the COVID-19 disease. There are 115 vaccine candidates and 155 molecules which are proposed to be in the R&D pipeline. The previously available drugs were also tested to be used to treat the diseases, one of such medication is Hydroxychloroquine, which is observing a higher demand that the earlier. This has presented huge opportunity for the manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Due to the rising demand for the vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is forecasted to witness a significant growth in the future.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The market is driven by the factors such as, rise in the prevalence of the chronic diseases, growth in the inclination towards biosimilars and biologics and the improvement in the recombinant products would help the market boost in the forecast period. Furthermore, the higher amount is getting invested on the R&D of the products which are segmented under the recombinant proteins, which is anticipated to help the market grow in the coming years. However, the lack of skilled medical professionals in the field of the recombinant proteins may hinder the industrial growth in the commenced period.
New product advancements to flourish the market
In October 2018, Leadiant Biosciences, Inc. announced that the Food and Drug Administration (FDA) had granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. The product Revcovi is a new enzyme replacement therapy (ERT) which can be used for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
In March 2020, AMS Biotechnology had announced the availability of recombinant proteins and antibodies for the detection of Coronavirus (COVID-19) and related RNA viruses. AMSBIO provides leading-edge life science technology, products and services for R&D in the medical, nutrition, cosmetics and energy industries.
Surge in mergers and acquisitions to boost the market
In August 2017, Sanofi has completed the acquisition vaccine development firm Protein Sciences which is in United States. The acquisition helps n expanding the company’s portfolio and helps in the cumulative effect of the distribution channels available for both of the companies, hence gaining maximum revenue in the coming years.
In August 2019, Nucleus Biologics, which is a leader in precision cell culture, is pleased to announce the acquisition of Primorigen Biosciences, Inc. The addition of Primorigen's Vitronectin XF and platform recombinant protein production technology will help Nucleus' strategy of offering traceable, reproducible and xeno-free (XF) cell culture ecosystems for the cell and gene therapy space.
Key benefits of the report:
- This study presents the analytical depiction of the global Recombinant Proteins industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Recombinant Proteins market share.
- The current market is quantitatively analyzed to highlight the global Recombinant proteins market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the Recombinant proteins market.
- The report provides a detailed global Recombinant proteins market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Recombinant Proteins Market research report:
- Who are the leading market players active in the Recombinant Proteins market?
- What are the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in tasking further strategic steps?
Recombinant Proteins Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Enzo Biochem, Inc (Enzo Life Sciences Inc.), Abcam PLC, Amgen Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk AS, ProSpec-Tany TechnoGene Ltd, Bio-Rad Laboratories Inc., Sanofi SA |
Loading Table Of Content...
